Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 4, 2005, Pages 417-419

  Pineda, Juan A ^a   Macías, Juan ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

AIDS; Antiretroviral therapy; HCV; HIV; Liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC LIVER DISEASE; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CLASSIFICATION; DRUG ERUPTION; FEVER; FIBROGENESIS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPEREOSINOPHILIA; HYPERSENSITIVITY REACTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INCIDENCE; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; METABOLIC DISORDER; NONHUMAN; PATIENT CARE; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; RISK REDUCTION; SUPERINFECTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS;

EID: 17444419439     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh555     Document Type: Article

References (16)

1. Bonacini, M. (2004). Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clinical Infectious Diseases 38, Suppl. 2, S104-8.
2. Macías, J., Melguizo, I., Fernández-Rivera, F. J. et al. (2002). Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients on potent antiretroviral therapy. European Journal of Clinical Microbiology and Infectious Diseases 21, 775-81.
3. Martínez-Sierra, C., Arizcorreta, A., Díaz, F. et al. (2003). Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clinical Infectious Diseases 36, 491-8.
4. Mohsen, A. H., Easterbrook, P. J., Taylor, C. et al. (2003). Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 52, 1035-40.
5. Martín-Carbonero, L., Benhamou, Y., Puoti, M. et al. (2004). Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clinical Infectious Diseases 38 128-33.
6. Macías, J., Castellano, V., Merchante, N. et al. (2004). Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 18, 767-74.
7. Marcellin, P., Asselah, T. & Boyer, N. (2002). Fibrosis and disease progression in hepatitis C. Hepatology 36, Suppl. 1, S47-S56.
8. Qurishi, N., Kreuzberg, C., Luchters, G. et al. (2003). Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362, 1708-13.
9. Sulkowski, M. S., Thomas, D. L., Mehta, S. H. et al. (2002). Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35, 182-9.
10. Dieterich, D. T., Robinson, P. A., Love, J. et al. (2004). Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clinical Infectious Diseases 38, Suppl. 2, S80-9.
11. Martínez, E., Blanco, J. L., Arnaiz, J. A. et al. (2001). Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 15, 1261-8.
12. Martín-Carbonero, L., Núnez, M., González-Lahoz, J. et al. (2003). Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clinical Trials 4, 115-20.
13. Sulkowski, M. S. (2004). Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clinical Infectious Diseases 38, Suppl. 2, S90-7.
14. Anon. (2001). Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2002. Morbidity and Mortality Weekly Report 49, 1153-6.
15. Tural, C., Fuster, D., Tor, J. et al. (2003). Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. Journal of Viral Hepatitis 10, 118-25.
16. Benhamou, Y., Martino, V., Bochet, M. et al. (2001). Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34, 283-7.